Latest Capital Raises News

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Thrive Tribe Technologies reported a $1.8 million half-year loss, driven by a major software impairment and ongoing operational challenges, while raising over $1.5 million in fresh capital to support its evolving business model.

ECS Botanics has reported a return to profitability and positive cash flow in the first half of FY26, driven by a strategic shift to branded products and major infrastructure expansion.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Sparc Technologies Limited reported a significant net loss of $1.86 million for the half-year ended December 2025, highlighting ongoing financial pressures despite continued R&D efforts. The company flagged material uncertainty over its ability to continue as a going concern.

Mayfield Group Holdings Ltd has reported a striking 52.8% increase in revenue and a 127.6% jump in profit for the half-year ending December 2025, driven by manufacturing growth and strategic acquisitions.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Terra Metals has raised $85 million through an institutional placement to fast-track exploration and development of its promising Southwest Prospect within the Dante Project in Western Australia.

Austral Gold Limited has reported a return to profitability in FY25, driven by the reopening of its Casposo Mine and a significant increase in gold equivalent production. The company also strengthened its balance sheet through a successful private placement and equity investments.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

Associate Global Partners Limited reported a significantly reduced half-year loss and modest growth in funds under management, underpinned by strong inflows and strategic capital raising.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.